Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...
Thomas M. Habermann, MD, is a hematologist with the Mayo Clinic in Rochester, Minnesota. A member of the Lymphoma Research Foundation Scientific Advisory Board, Habermann is well known as the lead ...
The patient had both classical Hodgkin lymphoma and diffuse large B-cell lymphoma. A rare case of collision lymphoma—2 morphologically and clinically distinct neoplasms in juxtaposition but without ...
Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial The combination of ...
A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma ...
Immunomedics IMMU, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, ...
—In a Danish registry study, patients with DLBCL who received R-CHOP-like therapies had an increased risk of infections, autoimmune conditions, and immune deficiencies compared with a matched ...
SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback